Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.

Publication Type:

Journal Article

Source:

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 52, Issue 6, p.896-900 (2011)

Keywords:

2011, Adult, Aged, Antibodies, Monoclonal, Antigens, CD20, Antineoplastic Agents, Bone Marrow, Bone Marrow Diseases, Clinical Research Division, Drug Resistance, Neoplasm, England, Europe, Female, Follow-Up Studies, Humans, Interferon Type I, Recombinant, Lymphoma, Non-Hodgkin, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Radioimmunotherapy, Radiometry, Radiopharmaceuticals, Remission Induction, Switzerland, United States

Abstract:

The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma.